v3.26.1
Warrants - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Mar. 21, 2023
Dec. 31, 2022
Mar. 31, 2026
Dec. 31, 2025
Jul. 21, 2025
Dec. 31, 2024
Nov. 21, 2023
Class of Warrant or Right [Line Items]                  
Warrants issued         2,753,246        
Warrants and rights outstanding, term (year)         6 months 21 days 9 months 21 days      
Common Stock [Member]                  
Class of Warrant or Right [Line Items]                  
Shares Issued, Price Per Share         $ 3.85        
PIPE Private Placement Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)       $ 10.8 $ 17,000        
Warrants issued       736,337 736,337        
Placement Agent Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)       $ 13.5          
Warrants issued       21,091 21,091        
Warrants and rights outstanding, term (year)       5 years          
Warrants or right, issued, percentage of shares purchased       7.00%          
Ladenburg Agreement Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)     $ 5.424            
Issuance of common stock under the March 2026 Public Offering Underwriters Option, net of issuance costs (in shares)   191,689              
Warrants issued     30,000            
Warrants and rights outstanding, term (year)     3 years            
Stock issued $ 1,100 $ 1,500 $ 500            
Cash payment to settle warrants         $ 1,100        
Preferred Tranche B Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year)               2 months 23 days  
Outstanding warrants           0   42,846  
Preferred Tranche C Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year) [1]         2 years 7 months 28 days 2 years 10 months 28 days      
Outstanding warrants         107,115 107,115   107,115  
Preferred PIPE Placement Agent Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)                 $ 6.3
Warrants issued                 850,119
Outstanding warrants         850,119 850,119   850,119  
Preferred PIPE Series B Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Outstanding warrants         1,483,000 1,500,000      
Release Date Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)             $ 218.75    
Preferred PIPE Series B Warrants Release Date [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year)             5 years    
Enrollment Date Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)             $ 175    
Preferred PIPE Series B Warrants Enrollment Date [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year)             5 years    
Private Placement [Member]                  
Class of Warrant or Right [Line Items]                  
Issuance of common stock under the March 2026 Public Offering Underwriters Option, net of issuance costs (in shares)       736,337          
Equity offering, combined purchase price (in dollars per share)       $ 10.8          
Equity offering, premium per share (in dollars per share)       $ 1.25          
Warrants and rights outstanding, term (year)       5 years          
Placement agent fee, percentage of gross proceeds       7.00%          
Proceeds from issuance or sale of equity       $ 8,000          
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year) 5 years                
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member] | Series A-3 Preferred Stock [Member]                  
Class of Warrant or Right [Line Items]                  
Outstanding warrants         107,115        
Aggregate exercise price         $ 107,100        
Maximum [Member] | Preferred PIPE Series B Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants issued             1,000,000    
Minimum [Member] | Preferred PIPE Series B Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants issued             500,000    
Public Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, number of securities called by each warrant or right (in shares)         1        
Class of warrant or right, exercise price of warrants or rights (in dollars per share)         $ 115        
Warrants or rights, redemption price (in dollars per share)         0.01        
Warrants and rights outstanding, minimum share price to call (in dollars per share)         180        
Pre-Funded Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)         0.0001        
Shares Issued, Price Per Share         $ 3.8499        
[1] Reflects a probability-weighted input derived from multiple Black-Scholes calculations. These calculations incorporate the Company’s estimated probability of dissolution, should SABS’ intellectual property fail to yield positive results in forthcoming clinical trials, potentially leading to dissolution before 2028. The probability was 47.5% as of March 31, 2026 and December 31, 2025.